The mixture was vortexed and then centrifuged at 10,000 g for 5 minutes. The supernatant was removed and immediately stored at −70°C. The remaining whole blood from EDTA tubes was then centrifuged at 1500 g at 4°C for 15 min to obtain plasma. Collection tubes containing no additive were allowed to clot at room temperature for 30 minutes and then centrifuged at 1500 g at 4°C for 15 min to obtain serum. Blood aliquots were stored at −70°C until assayed, except for homocysteine which was analyzed in fresh plasma using a competitive immunoassay format (Tri-State Clinical Laboratory Services, LLC, Cincinnati,

OH). Antioxidant capacity was analyzed in serum using the Trolox-equivalent antioxidant capacity (TEAC) assay using procedures outlined by the reagent provider (Sigma Chemical, St. Louis, MO). The coefficient of variation (CV) was 5.2%. For the analysis of glutathione, whole blood was first deproteinated Trametinib supplier using 5% metaphosphoric acid, as indicated above. The supernatant was then used to separately assay for TGSH and GSSG, and reduced glutathione (GSH) was calculated mathematically. For analysis of GSSG, supernatants were first neutralized with NaOH, and then 4-vinylpyridine was

mixed with the supernatant and incubated at room temperature for one hour in order to derivatize GSH. Assays for glutathione were performed using commercially available reagents (Northwest Life Science Specialties, Vancouver, WA). The CV for TGSH and GSSG was 3.2% and 4.9%, respectively. Statistical analysis This was a small exploratory KU-57788 supplier pilot/proof of concept study, and it was not expected that significant changes over time, or significant differences between treatment groups, would be observed unless the differences were very large. Therefore

the efficacy analysis described below should be considered only a formality; the main purpose of this study was to generate a general sense of the response of subjects to the two doses of MSM and to obtain estimates of endpoint variability and other parameters that could be used to inform the design of a larger, more definitive study, if one were to be carried out. The acute changes over the course of the testing visit, and the long-term changes over the course of a one-month MSM administration period, were tested for significance within each group, and between the two groups. Each outcome measure Cediranib (AZD2171) was tested using an analysis of covariance (ANCOVA), with the value of the variable at the end of the study being the dependent variable, the dose being the main factor, and the value of the variable at baseline being the covariate. The coefficient of the product (relative to dose) and its standard error of estimate were calculated from the ANCOVA. Significant product efficacy was inferred if this coefficient was significantly different from zero. Analyses were performed using “R” statistical software (version 2.13.1; R Foundation for Statistical Computing).